Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by SPCEO1on Sep 12, 2023 12:42pm
167 Views
Post# 35631812

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:New article in La Presse this morning

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:New article in La Presse this morning It looks like there actually has been a ban on insider trading at least since last December. There has been no insider buys or sells since then. I was told by THTX in mid-July that whenever the prohibition of insider trading was removed, the two execs would have 10 days to exercise and sell if they wanted to, so that seemed to be the deal with them as of mid-July. They may have, and should have in my opinion, decided subsequently to extend the time in which those options could be exercised after mid-July.  

It is also possible there were open windows of less than 10 days on multiple occaisions during the year that the two executives chose not to act during, but since they were less than 10 days the extension on them having to exercise those options got extended. To me, it seems more likely that the trading ban has been in effect the whole time since no executive or board memebr did any buying or selling since late last October..

PWIB123 wrote: I was going another direction with that question.  I don't believe they've had a continuous ban on insider trading for 9 whole months, and I believe they likely extended the option expiration dates.  I just can't get my head wrapped around a blackout period for this long even with the number of "potential" items they may be entertaining.  I don't think the board or the executive team showed up when they could've to send a signal to the market via insider trading, and consistent with their approach on maximizing bonuses and granting generous options, I believe they would be more likely to extend the option expiry.  This would be a more plausible explanation and align with the way Philippe chose to word his comments.


<< Previous
Bullboard Posts
Next >>